Colgate-Palmolive Company $CL Shares Bought by Bank of Montreal Can

Bank of Montreal Can increased its position in shares of Colgate-Palmolive Company (NYSE:CL) by 12.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,035,555 shares of the company’s stock after buying an additional 110,937 shares during the period. Bank of Montreal Can owned about 0.13% of Colgate-Palmolive worth $82,782,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. ProShare Advisors LLC raised its stake in shares of Colgate-Palmolive by 11.0% in the 3rd quarter. ProShare Advisors LLC now owns 2,047,542 shares of the company’s stock valued at $163,681,000 after purchasing an additional 202,379 shares in the last quarter. Providence Capital Advisors LLC bought a new stake in shares of Colgate-Palmolive in the 3rd quarter worth approximately $5,373,000. Asset Management One Co. Ltd. lifted its stake in Colgate-Palmolive by 3.9% in the third quarter. Asset Management One Co. Ltd. now owns 422,292 shares of the company’s stock valued at $33,758,000 after buying an additional 16,017 shares during the last quarter. Citigroup Inc. lifted its position in Colgate-Palmolive by 43.7% in the 3rd quarter. Citigroup Inc. now owns 1,346,590 shares of the company’s stock valued at $107,646,000 after purchasing an additional 409,710 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Colgate-Palmolive by 1.2% during the second quarter. Vanguard Group Inc. now owns 82,751,689 shares of the company’s stock worth $7,522,129,000 after buying an additional 993,432 shares during the period. 80.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Bank of America upped their price objective on shares of Colgate-Palmolive from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, February 2nd. Evercore raised their price objective on Colgate-Palmolive from $94.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, February 2nd. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Colgate-Palmolive from $83.00 to $90.00 and gave the stock a “hold” rating in a research report on Monday, February 2nd. UBS Group upped their price target on Colgate-Palmolive from $90.00 to $93.00 and gave the company a “buy” rating in a research report on Wednesday, January 14th. Finally, Rothschild & Co Redburn set a $93.00 price objective on shares of Colgate-Palmolive in a research note on Friday, February 13th. Eleven analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $94.75.

Colgate-Palmolive Stock Down 3.2%

Shares of CL stock opened at $89.55 on Thursday. The stock’s 50 day simple moving average is $89.71 and its 200 day simple moving average is $83.17. The company has a debt-to-equity ratio of 18.82, a quick ratio of 0.54 and a current ratio of 0.83. Colgate-Palmolive Company has a twelve month low of $74.54 and a twelve month high of $99.33. The company has a market capitalization of $72.19 billion, a price-to-earnings ratio of 34.18, a PEG ratio of 4.14 and a beta of 0.28.

Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings data on Friday, January 30th. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.04. The business had revenue of $5.23 billion during the quarter, compared to the consensus estimate of $5.13 billion. Colgate-Palmolive had a net margin of 10.45% and a return on equity of 353.72%. Colgate-Palmolive’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.91 EPS. As a group, research analysts predict that Colgate-Palmolive Company will post 3.75 EPS for the current year.

Insiders Place Their Bets

In other news, insider Sally Massey sold 15,851 shares of the stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $95.03, for a total value of $1,506,320.53. Following the completion of the sale, the insider directly owned 13,751 shares of the company’s stock, valued at approximately $1,306,757.53. This represents a 53.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Stanley J. Sutula III sold 97,843 shares of the stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $94.27, for a total transaction of $9,223,659.61. Following the completion of the sale, the chief financial officer directly owned 55,310 shares of the company’s stock, valued at approximately $5,214,073.70. This trade represents a 63.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 184,683 shares of company stock valued at $17,486,693 in the last three months. 0.34% of the stock is owned by corporate insiders.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.